Company Profile

BioCryst Pharmaceuticals Inc
Profile last edited on: 1/12/22      CAGE: 4GBX7      UEI: MGXADJ6SCLJ5

Business Identifier: Small-molecule toral herapies to block key enzymes involved in rare diseases
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4505 Emperor Boulevard Suite 200
Durham, NC 27703
   (919) 859-1302
Location: Multiple
Congr. District: 01
County: Durham

Public Profile

With facilities in Durham NC and in Birmingham, AL, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a biotechnology company, designing, optimizing, and developing small molecule drugs that block key enzymes involved in the pathogenesis of diseases particuarly those in rare diseases. BioCryst’s ongoing development programs include oral plasma kallikrein inhibitors for hereditary angioedema; avoralstat, BCX7353 and other second generation compounds, and BCX4430, a broad spectrum viral RNA polymerase inhibitor. The firm's product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza; BCX4161, an oral serine protease inhibitor, which is in Phase II clinical trial for hereditary angioedema (HAE); and BCX7353 and other second generation HAE compounds, which are oral serine protease inhibitors that are in preclinical trial for HAE. The company’s product candidates also comprise BCX4430, an RNA dependent-RNA polymerase inhibitor that is in Phase I clinical trial for treating Filoviruses, including Ebola and Marburg viruses; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir in Japan, Taiwan, and South Korea. In 2018, a much discussed merger between BioCryst and Idera Pharmaceuticals wasterminated after BioCryst stockholders voted against the planned combinatio

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2004 2 NIH $600,000
Project Title: Optimizing Hepatitis C virus NS5B Polymerase Inhibitors
2004 1 NIH $97,990
Project Title: Effects of TF/FVIIa Inhibition in CRP Transgenic Mice
1995 2 NIH $550,000
Project Title: Structure based design of inhibitors for complement protein D
1992 1 NIH $100,000
Project Title: Structure-Based Aldose Reductase Inhibitors
1991 1 NIH $75,000
Project Title: Structure-based design of inhibitors for flu neuraminidase

Key People / Management

  Jon P Stonehouse -- President and CEO

  Christopher S Arnold

  Y S Babu

  J Claude Bennett

  David W Borhani

  Charles Bugg -- Founder

  Michael A Darwin -- Chief Financial Officer, Treasurer, Secretary